If you want to play the game of resident downramper you need to...

If you want to play the game of resident downramper you need to make an effort and do some research first.

1. Those heart failure rates are based on old and crude measurements of the heart alone. New research looking at the effect of anathracyclines on the entire cardiovascular system has revealed that all patients suffer some level of permanent damage to their CV system. If you want references on this go and read the presentation from November 22 last year.

2. Dexrazoxane has been around for more than 30 years and it is basically not used. The reason why is it doesn’t offer any additional anticancer activity and potentially puts at risk the cancer treatment of the patient. This is where bisantrene is different in that it potentially offers both anticancer benefit plus cardioprotection. There is no need for any oncologist to put at risk the cancer treatment to protect the CV system of their patients.

3. The Triangle Research report did not say bisantrene would be used with every dose of doxorubicin. They were incredibly conservative in their market penetration estimation - when you actually calculate the peak uptake from their analysis it comes to a max of 3%.